Research Solutions of Arizona

Litchfield Park, Arizona 85340

3 studies enrolling now · 15 studies all time

What they study most

Atopic Dermatitis, Chronic Cough, Chronic Spontaneous Urticaria, Chronic Spontaneous Urticaria (CSU), Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Hereditary Angioedema, Hereditary Angioedema (HAE), Primary Immunodeficiency, Ulcerative Colitis

Studies at this site

• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines — Recruiting now
• Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab — Completed
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema — Completed
• Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks — Completed
• A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Running, not enrolling
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Running, not enrolling
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Running, not enrolling
• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• Evaluation of S-600918 in Adults With Refractory Chronic Cough — Completed
• Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) — Completed